FENDRR (Gene)

Entrez:400550

Description:FOXF1 adjacent non-coding developmental regulatory RNA

This gene produces a spliced long non-coding RNA transcribed bidirectionally with FOXF1 on the opposite strand. A similar gene in mouse is essential for normal development of the heart and body wall. The encoded transcript is thought to act by binding to polycomb repressive complex 2 (PRC2) and/or TrxG/MLL complexes to promote the methylation of the promoters of target genes, thus reducing their expression. It has been suggested that this transcript may play a role in the progression of gastric cancer. Alternatively spliced transcript variants have been identified. [provided by RefSeq, Mar 2015]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View FENDRR's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with FENDRR.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using FENDRR.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for FENDRR.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with FENDRR.

Results found

Linked to

	Label	Description
	GSE108464 AZ-628 11 v 12 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 9 v 14 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 12 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113215 GSE113217 KIT inhibition 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE197571 FOXM1 RNF112 overexpression MGC-803 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 0 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 5 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE108464 AZ-628 11 v 12 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 9 v 14 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 12 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE113215 GSE113217 KIT inhibition 2 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE197571 FOXM1 RNF112 overexpression MGC-803 2 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE226249 pirfenidone HL 0 v 8 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE226249 pirfenidone HL 5 v 6 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.